The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, …

DOSING & MONITORING GUIDE INDICATIONS1 Crohn’s Disease: SKYRIZI is indicated for the treatment of moderately to severely active Crohn’s disease in adults. Ulcerative Colitis: …

Jul 22, 2024 · These 2 randomized clinical trials compare the efficacy and safety of risankizumab vs placebo during an induction trial and a maintenance trial in patients with ulcerative colitis.

Jul 23, 2024 · Ulcerative colitis is a chronic inflammatory bowel disease characterized by inflammation and ulcers on the inner lining of the colon (large intestine).

For the treatment of Crohn’s disease and ulcerative colitis, evaluate liver enzymes and bilirubin at baseline and during induction (12 weeks). Interrupt treatment with SKYRIZI if drug-induced …

Jun 20, 2024 · Ulcerative colitis patients may experience some serious side effects with Skyrizi, including severe allergic reactions, an increased risk of infections, and liver problems.

Jun 18, 2024 · The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach …

Jun 19, 2024 · The US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa; AbbVie) for the treatment of moderately to severely active ulcerative colitis in adults. This …

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s …

Nov 28, 2025 · Potential Positives SKYRIZI® received positive reimbursement recommendations from Canada’s Drug Agency, enhancing access to treatment for ulcerative colitis for many …